-
Signature
-
/s/ Jennifer J. Rhodes, Attorney-in-Fact
-
Issuer symbol
-
ACAD
-
Transactions as of
-
16 May 2025
-
Net transactions value
-
-$50,000
-
Form type
-
4
-
Filing time
-
19 May 2025, 20:50:43 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Schneyer Mark C. |
EVP, CHIEF FINANCIAL OFFICER |
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO |
/s/ Jennifer J. Rhodes, Attorney-in-Fact |
19 May 2025 |
0001899977 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
ACAD |
Common Stock |
Sale |
$50,000 |
-2,000 |
-3.1% |
$25.00 |
62,130 |
16 May 2025 |
Direct |
F1, F2 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: